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Summary Four monoclonal antibodies (MAbs) from hybridoma obtained by in vitro stimulation of regional
lymph node lymphocytes from lung cancer patients and electrofusion of the stimulated cells with murine or
human -mouse myeloma cells were reactive to lung cancer cells in enzyme-linked immunoabsorbent assay, and
to lung cancer tissue in immunohistochemical analysis using acetone-methyl benzoate-xylene (AMeX) fixed
tissue and in immunofluorescence analysis. Three of the MAbs (designated ZLG40, 27D57 and 28K29)
recognised cell-surface antigens of the lung adenocarcinoma cell line A549 and the remaining one (designated
29D38) recognised nuclear membrane antigens of the same cell line. The three surface-binding MAbs showed a
significant complement-dependent cytotoxicity (CDC) to the A549 cells, but the membrane-binding 29D38
showed no CDC to the A549 cells. Western blotting of the extracts of the A549 or PC6 (small-cell lung cancer)
cell lines by the four MAbs showed a 28K29 antigen band at M, of approximately 600 000 (±2-ME), a ZLG40
antigen band at Mr 50 000 (±2-ME), and one 29D38 antigen band at Mr of more than 1 000 000 (-2-ME)
and Mr between 20 000 and 80 000 (+2-ME), but no detectable band for 27D57 antigen.
Keywords: human monoclonal antibody; cell surface antigen; nuclear membrane antigen; acetone-methyl
benzoate-xylene (AMeX); heterohybridoma
It is widely recognised that human monoclonal antibodies
(MAbs) specific for tumour-associated antigens and particu-
larly for cell surface antigens may be useful as in vivo
diagnostic or therapeutic tools, but efforts to obtain such
antibodies have been hampered by difficulties in their
detection and production (James et al., 1987; Hanna et al.,
1991). Screening for human MAbs is most commonly done
by immunohistochemical staining using formalin-fixed and
paraffin-embedded tissue sections of tumour specimens, but
this has generally resulted in the detection of MAbs specific
to cytoplasmic rather than cell surface antigens of cancer cells
(Hanna et al., 1991). Alternatively, frozen sections of tumour
tissues have been used for detection of membrane-binding
MAbs, but their preparation is generally difficult and time-
consuming and their microscopic observation is often
ambiguous because of difficulties in their immobilisation on
glass slides.
Sato et al. (1986), on the other hand, have reported
efficient detection of cell surface antigens of normal
lymphocytes using acetone fixation followed by clearance of
the acetone with methyl benzoate and xylene, largely free of
the destruction of cell surface antigens that generally occurs
with formalin fixation.
In the present study, we therefore investigated the use of
this AMeX method in the screening of MAbs for binding to
the membranes of cells from the tissue of lung cancer
patients, in addition to the conventional formalin fixation
and frozen tissue methods.
Human MAbs have been generated by various techniques,
generally involving: (1) fusion of murine, human-mouse or
human myeloma cells, originally developed by K6hler and
Milstein (1975); (2) transplanting of MAb-producing human
lymphocytes to severe combined immunodeficient (SCID)
mice (McCune et al., 1988; Duchosal et al., 1992); or (3)
phage display technology or genetic manipulation techniques
(McCafferty et al., 1990; Zebedee et al., 1992; Green et al.,
1994; Lonberg et al., 1994). Among these methods, one of the
most readily implemented is the fusion of human lympho-
cytes with murine or human-mouse myeloma cells, but it has
commonly suffered from inefficiency in the establishment of
MAb-producing hybridomas and instability in their MAb
production. As previously reported, we have found it possible
to increase the efficiency of establishment of such hybridoma
by prior in vitro stimulation of the human lymphocytes with
mitogens or interleukins (ILs) (James et al., 1987), and to
obtain stable MAb production by screening of the
hybridomas for production of MAbs bearing A-chain as the
L-chain subtype (Uchiyama et al., 1987; lizasa et al., 1990).
Here we describe the investigation of the effectiveness of
the use of the AMeX method in screening the MAbs for
binding to cell surface and nuclear membrane antigens of
cancer cells.
Materials and methods
Agents and cell lines
LPS (Escherichia coli 0127:B8) and HAT were purchased
from Sigma Chemical Co. (St Louis, MO, USA), SACI
(Pansorbin cells 507861) from Calbiochem (San Diego, CA,
USA), recombinant ILs and stem cell factor (SCF) from
Genzyme (Cambridge, MA, USA), fetal calf serum (FCS)
from Cytosystems (Castle Hill, Australia, cat. no. 15-010-
0500V), and bovine insulin, human transferrin and sodium
selenite from Cosmo-Bio Co. (Tokyo, Japan). The murine
myeloma cell line P3X63Ag8.653, the human-mouse
myeloma cell line SHM-D33, the human lung adenocarcino-
ma cell line A549, the human pancreas carcinoma cell line
PANC-1, the human colon carcinoma cell line SW1222 and
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the human lung diploid cell line W138 were obtained from the
American Type Culture Collection (Rockville, MD, USA).
The human lung adenocarcinoma cell lines PC9 and PC14,
the human lung squamous carcinoma cell line QG56, the
human lung large-cell carcinoma cell line PC13 and the
human small-cell lung cancer cell line PC-6 were obtained
from Immuno-Biological Laboratories (IBL) (Gunma,
Japan). The human lung adenocarcinoma cell line PC3 and
the human lung squamous carcinoma cell line EBC-1 were
supplied by the Japanese Cancer Research Resources Bank
(Tokyo, Japan). The ovarian carcinoma cell lines RMG-1
and RTSG were kindly supplied by Dr S Nozawa of Keio
University (Tokyo, Japan).
Lymphocytes
Regional lymph nodes from patients with primary lung
cancer were obtained aseptically at surgery. A single-cell
suspension (lymphocytes) in 10% FCS-supplemented RPMI-
1640 (Flow Laboratories) medium was prepared by passing
the lymph nodes through sterile steel mesh (no. 200) after
teasing with scissors.
In vitro stimulation of lymphocytes
Lymphocytes (2.5 x 106 cells ml-') prewashed with PBS were
resuspended in RDF medium (a 2:1:1 mixture of RPMI-1640,
DMEM and Ham F12) (Murakami et al., 1985) with 10%
FCS and 50 jgM 2-mercaptoethanol (2-ME). The cell
suspension was pipetted at 2 ml per well into 6-well tissue
culture plates and mitogens and ILs were added to the wells
as indicated in Table I, followed by incubation at 370C in
humidified 5% carbon dioxide air for the times indicated in
the table.
Cellfusion
Electrofusion of lymphocytes and mouse or human - mouse
myeloma cells was performed by the method of Foung et al.
(1990) and Zimmermann et al. (1990) with some modifica-
tions. Briefly, mixed cells (lymphocytes -myeloma
cells = 5 x 106: 5 x 106) were washed once with iso-osmolar
fusion medium (300L3; 280 mM sorbitol, 0.1 mM Ca2+
acetate, 0.5 mM Mg2' acetate and 1 mg ml-' BSA). After
collection by low-speed centrifugation, cell pellets were
resuspended in 2.5 ml of hypo-osmolar fusion medium
(75L3; 70 mM sorbitol, 0.1 mM Ca2+ acetate, 0.5 mM Mg2+
acetate, and 1 mg ml-' BSA). Five minutes later, 0.83 ml
aliquots of the cell suspension were placed in fusion chambers
and exposed to one rectangular electrical pulse (1 MHz,
1.00 kV cm-', 15 jis) in the model SSH-1 cell fusion
apparatus (Shimadzu Corporation, Kyoto, Japan). After
another 5 min standing, the three aliquots of cell suspension
(total volume 2.5 ml) were pipetted into 30 ml of HAT
medium (RDF medium supplemented with 100 gM hypox-
anthine, 16 gM thymidine, 0.2 jgM aminopterin, 5 jig ml-'
bovine insulin, 5 jig ml-' human transferrin, 5 ng ml-'
sodium selenite, 50 jiM 2-ME, 20 U ml-' IL-6, 40%
BALB/c mouse splenocyte culture supernatant and 10%
FCS) and then distributed in 0.1 ml portions into 96-well
culture microplates. Plates were incubated for 2-4 weeks in
humidified 5% carbon dioxide air at 37°C. Wells with
growing colonies were selected microscopically, production
of secreted immunoglobulin (Ig) was measured by a sandwich
ELISA and Ig-secreting wells were maintained in HT medium
(RDF medium supplemented with 100 gM hypoxanthine,
16 jiM thymidine, 5 jig ml-' bovine insulin, 5 ,ug ml-' human
transferrin, 5 ng ml-' sodium selenite, 50 ,uM 2-ME, 20 U
ml-' IL-6 and 10% FCS).
Cell culture and adaptation to serum-free medium
Heterohybridomas secreting Ig with A-chain were screened in
immunohistological and immunofluorescence methods as
described below. The selected hybridomas secreting Ig
reactive with lung cancer tissues and cell membrane or
nuclear membrane of A549 cells were recloned three times by
limiting dilution (0.5-2 cells ml-') in HT medium and finally
adapted to a serum-free medium, Hybridoma-SFM (Gibco-
BRL) supplemented with penicillin (50 IU ml-') and
streptomycin (50 jig ml-'). For 28K29 and 28B49 (a
negative control) cells, HT was further added to the serum-
free medium.
Measurement of Ig production and determination of Ab class
Human MAb was measured by a sandwich ELISA, in which
96-well ELISA microplates (Sumitomo Bakelite, Tokyo,
Japan) precoated overnight at 4°C with 2000-fold-diluted
goat antibodies to human Ig (Tago no.4103, Tago Inc.,
Burlingame, CA, USA) were blocked for 1 h at room
temperature with 2% BSA in PBS and washed twice with
PBS. Supernatants from the cell cultures, in serial 2-fold
dilutions by 0.2% BSA-PBS, were transferred to the wells
and incubated for 1 h at 37°C. The wells were then washed
three times, and bound MAb was detected by incubation for
30 min at 37°C with one of the following 1000-fold-diluted
alkaline phosphatase-conjugated goat Ab F(ab')2 anti-human
chains in 0.2% BSA-PBS: IgM p (Tago no.4602); IgG y
(Tago no.4600); IgA cx (Tago no.4601); Ig A (Tago no.4608);
Ig K (Tago no.4606). The plates were then washed three
times, followed by coloration with p-nitrophenyl phosphate
(Sigma) in 0.1 M diethanolamine buffer (pH 9.8) and human
MAb quantitation with human IgM (Cappel no.6001-1590,
Organon Technica Corporation, West Chester, PA, USA),
IgG (Cappel no.6001-0080) and IgA (Cappel no.6001-0020)
as the standards.
Cell ELISA
Wells with various cells grown subconfluently in 96-well
microplates (Sumitomo Bakelite Co., Tokyo, Japan) were
washed once with PBS, followed by standing for 15 min at
room temperature in PBS containing (0.05% glutaraldehyde
for cell fixation (Dorreen et al., 1982). Then, the wells were
washed three times with PBS containing 0.05% Tween 20
(Tween 20/PBS) and blocked with PBS containing 3% BSA.
After washing five times with PBS, 50 Ml aliquots of MAb-
containing samples were dispensed into each well. After
incubation for 3 h at room temperature, the wells were
washed three times with Tween 20/PBS, followed by the
addition of alkaline phosphatase (ALP)-conjugated goat
F(ab')2 anti-human Ig (Tago) diluted 1:1000 with 0.2%
BSA-PBS. After incubation for 1 h, the wells were washed
Table I Conditions of in vitro stimulation of human lymphocytes
Hybridoma Ab class Histologya Myeloma Mitogen Lymphokinesb Incubation (days)
ZLG40 IgM, A Sq P3X63Ag8.653 LPS (20 Mg ml') IL-4, 6 8
27D57 IgM, A Sq P3X63Ag8.653 LPS (20 Mg ml-,) IL-4 5
28K29 IgM, A Ad SHM-D33 SACI (1/10000? None 5
29D38 IgM, i Sq P3X63Ag8.653 LPS (20 jg ml- ) IL-1, 4, 7, SCF 5
28B49 IgM, A Ad P3X63Ag8.653 LPS (20 jg ml-l) IL-1, 4 5
aSq, squamous carcinoma; Ad, adenocarcinoma. bIL-4, 100 uml-'; IL-6, 100 u ml-'; IL-7, 100 u ml-'; SCF, 50 ngmlri.Human antibodies to membranous antigens
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three times and detection was accomplished using 100 pl of
a 0.67 M p-nitrophenylphosphate in 1 M diethanolamine
buffer (pH 9.6) containing 0.5 mM magnesium chloride.
After 10 min incubation, the reaction was stopped with
100 jul of 1 N sodium hydroxide and the reactivity of each
MAb to the cells was determined by measuring the
absorbance at 405 nm.
Immunohistochemical staining
Sections (5 gm) of lung tissues taken at surgery from lung
cancer patients were prepared by three different methods and
stained as follows.
In the preparation of frozen sections, tissues were placed
in Cryomold (Miles, Elkhart, IN, USA), covered with optical
cutting temperature (OCT) compound (Miles Inc.) and
immediately frozen in iso-pentane over liquid nitrogen and
stored at -80°C. Just before staining, cryostat sections
(5 ,um) were taken and placed onto precleared, 0.02% poly-L-
lysine (Mr< 150 000, Sigma)-treated microscope slides, where
they were fixed in 0.1 M phosphate buffer containing 4%
paraformaldehyde (PFA) for 20 min at room temperature
and then washed three times in PBS.
To prepare AMeX-fixed sections (Sato et al., 1986), tissues
were first fixed in acetone precooled to 4°C and stored at
-20°C for 1-3 days. On removal from storage they were
dehydrated by two cycles of acetone, followed by acetone
removal in two cycles of 15 min immersion in methyl
benzoate followed by 15 min in xylene, and then embedded
in paraffin by the usual procedure. Sections (5 tm) of the
paraffin-embedded tissues were taken, deparaffinised by
xylene and acetone, and fixed in 4% PFA for 5 min. They
were then prepared for staining by washing in water and
PBS.
Formalin-fixed sections were prepared in the usual
manner. Tissues were fixed in 10% formalin solution and
embedded in paraffin, and sections (5 tim) of the embedded
tissues were taken and then deparaffinised by xylene and
ethanol in series and then washed in water and PBS.
In all three cases, immunostaining was performed as
follows. The washed tissue sections were blocked with 10%
normal goat serum (Nichirei, Tokyo, Japan) for 20 min at
room temperature, followed by the addition of MAb (0.5-
20 Mg ml-') test samples. After incubation for 18 h at 4°C in
a moisturised atmosphere, the sections were washed three
times with PBS. Peroxidase-conjugated goat F(ab')2 anti-
human Ig (Cappel no. 3301-0231) diluted 1:1000 (v/v) in
0.2% BSA-PBS was layered on the washed sections. After
incubation for 2 h at room temperature and washing three
times with PBS, the sections were colorated with a substrate
solution for peroxidase (0.02% diaminobenzidine and
0.005% hydrogen peroxide in 50 mM Tris-HCL buffer,
pH 7.6), incubated for 5 min, washed with water, and
counterstained with Harris-type haematoxylin solution
(Sigma). The sections were then washed thoroughly with
tap water and dehydrated with a graded series ofethanol and
xylene. A cover glass was mounted on each slide with xylene-
based Mount Quick (Daido-Sangyou, Tokyo, Japan), for
microscopical observation.
Immunofluorescence
A549 cells grown subconfluently in DMEM containing 10%
FCS in T-75 culture bottles were incubated with PBS
containing 0.02% EDTA for 10-20 min, then scraped and
collected by centrifugation at low speed. Aliquots of 2 x 105
A549 cells were resuspended in 150 Ml supernatant containing
MAb (0.5-20 Mg ml-'), followed by incubation for 2 h at
4°C. The cells were pelleted by centrifugation at low speed
and resuspended in 100 pl of FITC-conjugated goat F(ab')2
anti-human Ig (Cappel). After incubation for 1 h at 4°C, the
cells were washed three times with PBS and resuspended in
50 ,l of PBS for observation with an Axioscop (Zeiss,
Germany) fluorescence microscope.
CDC activity
A549 cells grown subconfluently in 10% FCS-supplemented
DMEM in four T-75 culture bottles were collected as
described above for immunofluorescence, and resuspended
at a density of 1 x 106 cells ml-' in DMEM devoid of phenol
red in the absence of FCS. Aliquots (100 Ml) of the cell
suspension were dispensed in 96-well microplates and 10 Mg
ml-' of each MAb and 10% low-toxic rabbit complement
(Cederlane, Ontario, Canada) were added to each well,
followed by incubation for 2 h at 37°C in humidified 5%
carbon dioxide air. Viable cells were then counted by
colorimetric assay using sodium 3'-[1-(phenylamino-carbo-
nyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulpho-
nic acid (XTT), Cell Proliferation kit II (Boehringer
Mannheim, Germany) (Stevens et al., 1993; Buttke et al.,
1993). A 50 pl solution of XTT was next added to each well
and incubation was continued for another 4 h. Absorbance at
450 nm was then measured, and CDC activity was expressed
as the percentage difference between incubations with and
without MAb.
Preparation of cell extracts
Subconfluent A549 or PC-6 cells grown in 5% FCS-
supplemented RDF medium in four T-75 culture bottles
were collected as described in the section on immunofluor-
escence. Approximately 5- 10 x 107 cells were resuspended in
1 ml of PBS containing 1% Triton X100, 5 Mg ml-1
leupeptin, 5 /g ml-' chymostatin, 5 Mg ml-' pepstatin and
1 mM phenylmethylsulphonyl fluoride (PMSF), and incu-
bated for 45 min on ice with intermittent shaking. Super-
natants were collected by centrifugation at 27 000 g for
5 min, detergent was removed with an SM-2 Econo-column
(Japan Bio-Rad, Tokyo, Japan), and the cell extracts were
used for immunoblotting.
Biotin labelling of MAb
MAb solution purified from supernatants (2 1) of hybridoma
grown in a serum-free medium using a hydroxylapatite
column was buffer-exchanged to 50 mM bicarbonate buffer
(pH 8.5) and concentrated to 2 mg ml-' with a Centricon-30
(Millipore). An aliquot (74 Ml) of 1 mg ml-' NHS-LC-biotin
(Pierce, Rockford, IL, USA) was added, followed by
incubation for 2 h on ice. The reaction mixture was
centrifuged (10 000 g, 30 min) with a Centricon-30 to
remove free biotin, and the concentrated solution was
diluted in 10 mM phosphate buffer containing 150 mM
sodium chloride and 0.1% sodium azide. The incubation-
28K29
27D57
ZLG40
29D38
28B49
hIgM 1, I lI. I
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Figure 1 Reactivity of MAbs to glutaraldehyde-fixed A549 cells.
All MAbs except the 28B49 isotype-matched negative control
reacted with the glutaraldehyde-fixed A549 cells (a lung
adenocarcinoma cell line). Neither 28B49 MAb nor the other
negative control, hIgM (polyclonal Ab, Cappel), reacted with the
cells. All data shown as means±s.d. (bar) of three data points.Human antibodies to membranous antigens
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centrifugation-dilution cycle was performed three times, to
obtain biotinylated MAb for use in immunoblotting.
Immunoblotting
Detergent-free extracts of A549 or PC-6 cells were diluted 5-
fold with an SDS sample buffer [0.0625 M Tris-HCl buffer
(pH 6.8) containing 10% glycerol, 2% SDS and 0.005%
bromophenol blue with or without 5% 2-ME] and boiled for
3 min. After rapid cooling, 5 ,l was applied on each lane of
2- 15% or 4-20% SDS-polyacrylamide gel and electrophor-
esed by the method of Laemmli (1970). Electroblotting from
the gel to Immobilon-P membrane (Millipore) was performed
(Towbin et al., 1979) using an SDS-PAGE buffer containing
20% methanol on a semi-dry blotting apparatus (Bio-Rad).
After electroblotting, the membranes were blocked with
0.02% Tween 20/PBS containing 0.5% skim milk for
30 min at room temperature. Biotinylated MAb (1 jug ml-')
diluted in 0.02% Tween 20/PBS containing 0.5% skim milk
was added and incubated for 1 h, followed by washing three
times with 0.02% Tween 20/PBS. An alkaline phosphatase-
conjugated streptavidin (Jackson ImmunoResearch Labora-
tories) solution diluted 1:500 (v/v) in 0.02% Tween 20/PBS
containing 0.05% skim milk was added, and incubation was
continued for 30 min. The membranes were washed three
times with 0.02% Tween 20/PBS, followed by coloration
using 10 ml of 0.5 M diethanolamine (pH 9.8) supplemented
with 30 ,ul each of BCIP (50 mg ml-' of dimethylformamide)
and NTB (75 mg ml-' of 70% dimethylformamide). The
reaction was stopped by washing with water.
N-terminal amino acid sequenving
Aliquots (20 ,ug) of each MAb were electrophoresed on a
12.5% isocratic SDS-polyacrylamide gel under reducing
conditions, and proteins on the gel were blotted to
Immobilon'sQ (Millipore) PVDF membrane by the method
Figure 2 Immunofluorescence staining patterns in the lung adenocarcinoma cell line A549. Indirect immunofluorescence staining of
A549 cells shows positive reactivity of MAbs to the cell surface (a, 28K29 MAb; b, ZLG40 MAb; c, 27D57 MAb) and to the
nuclear membrane (d, 29D38 MAb). The negative control 28B49 MAb did not react with the cells (e). (x 300).Human antibodies to membranous antigens
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Table II Cell ELISA using various human cell lines
Cell line (histology) ZLG40 27D57 28K29 29D38 28B49
PC3 (lung adenocarcinoma) +
PC9 (lung adenocarcinoma) + + + +
PC14 (lung adenocarcinoma) + + + + +
A549 (lung adenocarcinoma) + + + + +
EBC-1 (lung squamous carcinoma) + + +
QG56 (lung squamous carcinoma) + + + + +
PC13 (large-cell lung carcinoma) + + + + +
PC6 (small-cell lung carcinoma) + + + + + +
PANC-1 (pancreas carcinoma) + + + +
SWI222 (colon carcinoma) + + +
RMG-1 (ovarian carcinoma) + + + +
RTSG (ovarian carcinoma) + + + +
W138 (lung diploid fibroblast) + + +
Cell ELISA using various cells was performed as described in Materials and methods. MAb reactivity with each cell
line was classified into negative (-), and weakly (± ), moderately (+) and strongly (+ +)positive on an arbitrary scale.
of Hirano et al. (1990). After staining of the blotted
membrane with Coomassie brilliant blue solution, heavy
and light chains of each MAb were excised for analysis of N-
terminal amino acid sequences with the Protein SequencerPSQ
(Shimadzu Corporation, Kyoto, Japan).
Results
Preliminary generation and screening
Electrofusion of the regional lymph node lymphocytes from
seven patients with primary lung cancer, stimulated with
mitogens or mitogens plus ILs, and the murine myeloma cell
line (P3X63Ag8.653) or the human-mouse heteromyeloma
cell line (SHM-D33) resulted in the generation of 2114 Ig-
producing hybridomas. The MAbs produced by these
hybridomas were screened for (1) constituent A-chain; (2)
reactivity in cell ELISA to the glutaraldehyde-fixed A549
lung adenocarcinoma cell line; (3) immunofluorescent
staining of the A549 cell or nucleus membrane; and (4)
immunohistochemical staining of the cancerous but not the
non-cancerous parts of lung cancer tissue sections prepared
by freezing, formalin fixation or AMeX fixation. Nine of the
Ig-producing hybridomas satisfied all of these criteria, and
four were prepared for the present study by recloning them
three times and adapting them to the serum-free medium
Hybridoma-SFM (GIBCO).
Table I shows the lymphocytes, mitogens and ILs used to
obtain these four hybridomas secreting human MAbs
(ZLG40, 27D57, 28K29 and 29D38) showing specificity to
lung cancer cells and tissue, together with those used to
obtain the hybridoma cell line 28B49 as an isotype-matched
negative control. As shown in Figure 1, the four MAbs
(1.0 jg ml-') selected from the screening all reacted with
glutaraldehyde-fixed A549 cells grown in 96-well microplates,
while the two controls 28B49 (IgM, A) and hIgM (human
polyclonal IgM) showed no reactivity to the cells. Table II
shows the results of cell ELISA using various human cell
lines.
As illustrated in Figure 2a-d, immunofluorescent staining
showed three of the four selected MAbs (28K29, 27D57 and
ZLG40) to recognise A549 cell surface antigen, and the
fourth MAb (29D38) recognised nuclear membrane antigen
of the same cell line. No cellular fluorescence was observed
with the control MAb, 28B49 (Figure 2e).
Immunohistochemical study
The results of immunohistochemical staining with AMeX,
frozen and formalin fixation are summarised in Table III.
The MAb 28K29 reacted with most of the tissue sections of
lung cancer tested, regardless of the fixation method, but the
other three MAbs (ZLG40, 27D57, 29D38) reacted with
Table III Immunohistostaining of lung cancer tissue sections
Frozen AMeX Formalin
Antibody Ad Sq Ad Sq Ad Sq
28K29 2/3 2/2 3/3 2/3 3/3 3/3
27D57 2/3 2/2 2/3 1/3 0/3 0/3
ZLG40 2/3 1/2 1/3 3/3 0/3 0/3
29D38 2/3 2/2 3/3 3/3 0/3 0/3
28B49 0/3 0/2 0/3 0/3 0/3 0/3
hIgM 0/3 0/2 0/3 0/3 0/3 0/3
Lung adenocarcinoma and lung squamous carcinoma tissue were
fixated by the freezing, AMeX and formalin methods; number of
sections with positive staining/total number of sections tested.
Table IV N-terminal amino acid sequences
H chain
28K29 N-blocked
29D38 N-blocked
27D57 EVQLV-QSGAQ-VKKPG-EQLKI-
ZLG40 EVQLV-QSGAQ-VXPPG-
28B49 EVQLV-QSGGV-LVQPG-
V(H) -EVQLV-QSGAE-VKKPG-ESLKI-
L Chain
28K29 N-blocked
29D38 SYELT-QPPSV-SVSPG-QTARI-TXEGD-ALPK
27D57 SYELT-QPPSV-SVS
ZLG40 SYELT-QP
28B49 N-blocked
Ig (A) -SVELT-QPPSG-SVSPG-KTARI-TCSGD-ALPKK-
N-terminal amino acid sequences of five MAbs including the
negative control 28B49 were determined. The known sequences of
human germline V(H) (Berman et al., 1991) and human Ig (A)
(Combriato et al., 1991) with high homology to the MAbs sequenced
in this study were comparatively aligned.
tissue sections fixed by freezing and by AMeX, but not with
those fixed by formalin.
Representative patterns of the staining with AMeX are
shown in Figure 3. All four MAbs reacted with the tissue
sections fixed by this method. AMeX fixation resulted in a
clear staining of cytoplasmic rather than cell surface regions
(Figure 3a,c,d and e) by all four MAbs, and also an apparent
staining of the luminal regions of membranes by the MAb
28K29 (Figure 3b), indicating that the corresponding antigens
to the four MAbs are localised in both membranous and
cytoplasmic regions of cancer cells.
The four MAbs were also tested for immunoreactivity in
frozen sections of normal mammary gland, stomach, lung
and kidney tissues, with negative results in all cases. None of
the four stained any of the cells of normal mammary ductal,
gastric epithelial, bronchiolar epithelial or proximal tubular
tissues (data not shown).Human antibodies to membranous antigens
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Figure 3 Immunoperoxidase staining patterns in AMeX-fixed tissue sections of lung adenocarcinoma. AMeX-fixed and paraffin-
embedded sections (5pm thick) of lung adenocarcinoma tissues (ALAI and ALA2) were reacted for reactivity of MAbs. 28K29
MAb shows positive reactivity to the cytoplasm parts of tissue section (a, ALAI tissue section) and to the luminal membranes of
another tissue section (b, ALA2). Similarly, the cytoplasmic parts of ALAI tissue section (a) and to the luminal membranes as well
as the cytoplasm ofALA2 (b). ZLG40 MAb (c), 27D57 MAb (d) and 29D38 (e) reacted with the cytoplasm of ALAI tissue sections.
No positive staining of ALAI section was observed in case of 28B49 (f) (x 170).
CDC activity
The complement-dependent cytotoxicity of the four MAbs, as
determined by incubating the A549 adenocarcinoma cells
with the MAb (1 ,ug ml-') and 10% rabbit complement for
2 h at 37°C, counting the residual viable cells by the XTT
method (Stevens et al., 1993; Buttke et al., 1993), and
calculating the CDC on this basis, is shown in Figure 4. The
CDC was high with the three cellular membrane-binding
MAbs (approximately 30% with 28K29 and ZLG40 and
approximately 12% with 27D57), but was only 3-6% with
the nuclear membrane-binding MAb 29D38 and with the
negative control MAb 28B49, and thus practically indis-
tinguishable from background level CDC.
Antigen immunoblotting
Antigens for three of the four MAbs were identified by
immunoblotting, as shown in Figure 5. The cell extracts were
obtained from the lung adenocarcinoma cell line A549 and
from the small-cell lung carcinoma cell line PC-6 by exposure
to the detergent 1% Triton X100 and its removal with an
SM-2 column. The cell extracts were run on 2-15% or 4-
20% SDS-polyacrylamide gel, and the electrophoresed gel
was blotted to PVDF membrane for the detection of bands
immunoreactive to each MAb. The MAbs 28K29 and ZLG40
reacted with bands of approximately 600 000 and 50 000,
respectively, under both non-reducing and reducing condi-
tions. The MAb 29D38 bound to one or more substances ofmore than 1 000 000 at the gel top under non-reducing
conditions, and to several bands between 20 000 and 80 000
under reducing conditions. The MAb 27D57 did not react
with any band either the A549 or the PC-6 cell extract (data
not shown).
N-terminal amino acid sequences
Table IV shows the results of the N-terminal sequencing of
the four cell-reactive MAbs and the negative control 28B49,
as determined by SDS-PAGE and the blotting to PVDF
membrane followed by analysis with an automatic amino
acid sequencer. The N-terminal amino acids of both the H-
chain and the L-chain of MAb 28K29 were found to be
blocked. The N-terminal amino acid sequences of the L-
chains of 27D57, ZLG40 and 29D38 were identical as far as
examined. As also shown in Table IV, a search of known
28K29
27D57
ZLG40
29D38
28B49
hIgM
0 5 10 15 20 25
CDC activity (%)
30 35 40
Figure 4 CDC activity of MAbs (1 Mg ml-1) against adenocarci-
noma A549 cells in the presence of 10% rabbit complement. A549
cell surface-binding MAbs (28K29, 27D57, and ZLG40) show
significant CDC activity. A549 nuclear membrane-binding MAb
(29D38) and two negative control Abs (28B49 MAb and hIgM)
do not show CDC activity. All data shown as mean+s.d. (bar) of
three data points.
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amino acid sequences showed a high homology between the
N-terminal amino acid sequences of the H-chains of MAbs
27D57 and ZLG40 and the human germline V (H) (Berman
et al., 1991), and between those of the L-chains of MAbs
29D38, 27D57 and ZLG40 and human Ig (A) (Combriato et
al., 1991).
Discussion
The primary objective of the present study was the
establishment of heterohybridoma cell lines producing
human MAbs specific for cell-surface or nuclear membrane
antigens of the lung adenocarcinoma cell line A549, from
hybridomas generated by electrofusing the lymph node
lymphocytes of lung cancer patients, stimulated in vitro with
mitogens or mitogens plus lymphokines, with the readily
available murine or human-mouse myeloma cells. A
secondary objective, which proved important to the
successful screening for such hybridomas, was the applica-
tion of the AMeX method of Sato et al. (1986) to the fixation
of solid tumour specimens consisting of cancerous tissues
from lung cancer patients, to permit efficient detection of
MAbs bound to cell-surface or nuclear membrane antigens.
In the effort to obtain human MAbs specific for tumour-
associated antigens, immunohistochemical methods are
generally preferable for the detection of cell-surface-binding
MAbs. Among the several methods of tumour tissue fixation
available for this purpose, formalin fixation has been most
commonly employed because formalin-fixed tissue sections
are easy to handle and familiar to many pathologists, even
though it tends to involve inactivation or aggregation of the
target antigens. Freezing has been used as an alternative
method to avoid these problems, but immunohistochemical
investigation of frozen tissue sections is often hindered by
their fragility under the immunohistochemical staining
procedure and by their incomplete or insecure immobilisa-
tion for microscopic observation.
The AMeX method was originally developed for the
fixation of cell surface antigens of lymphocytes, but its
adoption in the present study for the fixation of tissue
sections of solid lung cancers showed it to be highly effective
in screening for MAbs that recognise cell-surface or nuclear
membrane antigens, as three of the four MAbs later
3 4 5 6
Figure 5 Immunoblotting analysis of antigens. Cell extracts ofPC6 (lanes 1 and 2) and A549 (lanes 3-6) were run on SDS-PAGE
followed by Western blotting (lanes 1 and 2, 2-15% acrylamide gel; lanes 3-6, 4-20% acrylamide gel). The MAbs used were
28K29 (lane 1 and 2), ZLG40 (lane 3 and 4) and 29D38 (lanes 5 and 6). Lanes 1, 3 and 5 were obtained under non-reducing
conditions and lanes 2, 4 and 6 under reducing conditions.
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confirmed to be reactive with the A549 cells showed positive
reactivity to tissue prepared by AMeX fixation (and also to
those prepared by freezing), but not to tissue prepared by
formalin fixation.
The present study also served to confirm the usefulness of
LPS for stimulation of human lymphocytes before electrofu-
sion to obtain hybridoma for MAb production. Many
investigators have reported on the in vitro stimulation of
human lymphocytes for this purpose (James et al., 1987), but
generally by SACI rather than LPS, as it is known that B-
cells are activated by the polyclonal human B-cell activator
SACI (Ruuskanen et al., 1980; Schuurman et al., 1980) but
not by the polyclonal murine B cell activator LPS (Umetsu
and Geha, 1987).
In our own studies, however, we have chosen to employ
LPS as well as SACI because regional lymph node
lymphocytes, as our source of B cells, also include immune
cells such as T cells and monocytes, and it therefore seemed
reasonable to presume that indirect stimulation of human B
cells might occur in the presence of LPS, probably via
activation of monocytes which have been shown to have the
cell-surface marker CD14, which is known as a receptor for
LPS (Ziegler-Heitbrock et al., 1993). The results of the
present study indicate that LPS is effective for such
activation, at least when used in combination with
lymphokines such as IL-4, IL-6 and IL-7. On this basis, we
have now begun a systematic study to determine the
combinations of mitogens and lymphokines most effective
for this purpose (Yoshinari et al., 1996).
The productivity of the four hybridomas secreting reactive
MAbs, following their recloning three times and adaptation
to the serum-free medium Hybridoma-SFM (GIBCO-BRL),
was: 29D38, 20-40 jug ml-'; 28K29 and 27D57, 5-20 tg
ml-'; and ZLG40, 0.5-2 ,ug ml-'. Their MAb production in
cell culture was found to be stable in the long term, for
periods of up to 18 months or more. It may be noted, also,
that the same hybridomas were found to be capable of
producing MAbs in the ascites fluid of SCID mice following
i.p. injection, at production levels of: 29D38, 20-40 mg per
mouse; 28K29 and 27D57, 1-3 mg per mouse; ZLG40, less
than 1 mg per mouse.
The results of the immunoblotting analyses provide certain
insights into the identity and nature of the antigens for three
of the four reactive MAbs. The analyses showed the 28K29
antigen to have Mr of approximately 600 000 on SDS-PAGE
under both non-reducing and reducing conditions, thus
suggesting that it may be a mucin-type tumour-associated
antigen (Rughetti et al., 1993; Tytgat et al., 1994). The
ZLG40 antigen had Mr of 50 000 under both non-reducing
and reducing conditions. Cytokeratins of 40-68 000 (Moll et
al., 1982; Ramaekers et al., 1983; Haspel et al., 1985; Broers
et al., 1988; Pomato et al., 1989; Erb et al., 1992) have been
proposed as possible tumour-associated antigens, among
which cytokeratins nos. 14 and 15 have Mr of 50 000.
Against this, however, it must be noted that the immuno-
fluorescence analyses showed the ZLG40 antigen to be
localised at the cell surface of the A549 cells, thus suggesting
that the ZLG40 antigen is not a cytokeratin as mentioned
above.
The 29D38 antigen had M, of more than 1 000 000 under
non-reducing conditions and between 20 000 and 80 000 in
several major immunoreactive bands under reducing condi-
tions. Recent findings show that 26S proteasome localised in
the cytoplasm of cells has Mr of 2 000 000 and is comprised
of several protein components ranging from 22 000 to
110 000 Mr (Peters et al., 1993, 1994; Rechsteiner et al.,
1993; Rivett, 1993; Kristensen et al., 1994). The immuno-
fluorescence analysis, however, again showed that the 29D38
antigen was localised at the nuclear membrane of A549 cells,
and thus suggested that the antigen would not be a
proteasome itself, but that it may be a proteasome-like
substance which is closely associated to tumour antigens. On
the other hand, 27D57 antigen was not detected in cell
extracts of A549 and PC6 cells. In summary, the results of
the present study provide a basis for further study and
characterisation of the antigens to three of the four MAbs,
the exception being 27D57 antigen, which was not detected in
the cell extracts of either A549 or PC6 by immunoblotting.
From the biological point of view, the results of the CDC
activity were consistent with those of the immunofluorescence
analyses. The three MAbs that bound to the cell surface of
the A549 cells showed significant CDC to A549 cells, in
varying degrees, while the MAb that bound to the nuclear
membrane showed no CDC to A549 cells. In a related study
now in progress, moreover, preliminary data on the
biodistribution of the same human MAbs injected i.v. into
A549 tumour cell burden SCID mice show significant
accumulation of all four MAbs in the proliferated sites of
A549 cells following their s.c. injection, but no such
accumulation of a negative control MAb.
In conclusion, four human MAbs specific for cell surface
or nuclear membrane of the lung adenocarcinoma cell line
A549 were found and the heterohybridomas generating these
MAbs were established, following their selection in an
extensive screening of MAbs for A-chain constituents of
their L-chain and reactivity to tissue sections of lung cancer
prepared by AMeX fixation. The four heterohybridomas thus
obtained were shown to be capable of efficient, stable long-
term production of these MAbs, and AMeX fixation was
shown to facilitate the detection of MAbs specific for cell
surface and nuclear membrane antigens whose detection has
heretofore been difficult or impossible.
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